RNAI Medicine

Genesis Research and Development says it is confident it can close a deal with an overseas investor to help fund its research into gene silencing technology.

July 1 – Genesis Research and Development Corp., the Auckland-based biotechnology company, will tap an international venture capital group to partner on a new subsidiary to undertake its gene silencing project.

Australian scientists have developed a "trojan horse" therapy to combat cancer, using a bacterially-derived nano cell to penetrate and disarm the cancer cell before a second nano cell kills it with chemotherapy drugs

The Max Planck Society , Max Plank Innovation, and Alnylam Pharmaceuticals are suing a trio of Massachusetts research institutions for allegedly breaching their contractual and fiduciary duties in prosecuting patents surrounding RNA interference technology.

London, June 29 : Aussie scientists have developed a new therapy that uses minicells to deliver cancer drugs, in order to prevent resistance in cancer cells.

A new therapy to treat cancer has been developed by Australian scientists and it promises to have far fewer unpleasant side effects than conventional treatments and should also be much cheaper.

Source: Reuters By Michael Perry SYDNEY, June 29 (Reuters) - Australian scientists have developed a "trojan horse" therapy to combat cancer, using a bacterially-derived nano cell to penetrate and disarm ...

Alnylam Pharmaceuticals Inc. reports it has joined in a lawsuit with the Max Planck Society against the Whitehead Institute for Biomedical Research, MIT, and the University of Massachusetts over the handling of RNAi-related patent applications.

CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has joined with the Max Planck Society in taking legal action toward the Whitehead Institute for Biomedical Research.

The patent, its abstract states, claims "a method of selectively labeling non-messenger RNA molecules by isolating total RNA from a tissue or cell, dissolving the isolated RNA, blocking the 3' end of the RNA, and adding T4 RNA ligase and a labeled nucleic acid adaptor."